Figure 1.

Overview of Study Design, Pathological Changes, and Gating Strategy

(A) Historical flow cytometry data from the bleomycin mouse model were pooled and collectively analyzed. Samples were collected 3, 14, or 21 days afterbleomycin or saline administration from the compartments BALF (159 samples) and lung tissue (144 samples). Five different C57BL/6 substrains were included.

(B) Representative Masson's trichrome staining of lung sections, showing pathologic alterations in the bleomycin model. Zoomed images exemplify the increasing fibrosis accumulation from day 3–21 after bleomycin challenge; scale bar represents 1 mm and 100 μm, respectively. High-resolution versions of these images for use with the Virtual Microscope are available as eSlides: VM06176, VM06160, VM06162, VM06177.

(C) Representative flow cytometry gating strategy. The 16 cell populations taken for further analysis are highlighted in bold. Alveolar macrophages (AM), dendritic cells (DC), interstitial macrophages (IM), monocyte-derived AM (MoAM), monocyte-macrophages (MoMp), neutrophils (PMN); forward scatter (FSC), area (A), height (H), side scatter (SSC), and monolymph gate (ML).

See also Table S1 for overview of group distribution and Table S2 for antibody details.